Cancer immunotherapy with mRNA-transfected dendritic cells

Immunological Reviews

Volumn 199, Issue , 2004, Pages 251-263

  Gilboa, Eli ^a   Vieweg, Johannes ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; LIPID; MESSENGER RNA; TUMOR ANTIGEN; VACCINE;

ACTIVE IMMUNIZATION; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPARATIVE STUDY; DENDRITIC CELL; DRUG EFFICACY; ELECTROPORATION; GENE AMPLIFICATION; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; KIDNEY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY; URINARY TRACT CANCER; VACCINATION; VALIDATION PROCESS;

ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 2942559009     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00139.x     Document Type: Review

References (85)

1. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-472.
2. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177-1182.
3. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998; 16:364-369.
4. Saenz-Badillos J, Amin SP, Granstein RD. RNA as a tumor vaccine: a review of the literature. Exp Dermatol 2001;10:143-154.
5. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000;60:1028-1034.
6. Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther 2000;7:2028-2035.
7. Thornburg C, Boczkowski D, Gilboa E, Nair SK. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy. J Immunother 2000;23:412-418.
8. Weissman D, et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol 2000;165:4710-4717.
9. Su Z, Peluso MV, Raffegerst SH, Schendel DJ, Roskrow MA. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol 2001;31:947-958.
10. Heiser A, et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000;164:5508-5514.
11. Nair SK, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000;6:1011-1017.
12. Zeis M, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003;170:5391-5397.
13. Siegel S, et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematological malignancies. Blood 2003;102:4416-4423.
14. Su Z, et al. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 2002;62:5041-5048.
15. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000;165:5713-5719.
16. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003;102:964-971.
17. Zitvogel L, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998;4:594-600.
18. Dranoff G, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
19. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278:117-120.
20. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998;95:9482-9487.
21. Zitvogel L, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
22. Akiyama K, et al. Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 2003;170:1641-1648.
23. Granstein RD, Ding W, Ozawa H. Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 2000;114:632-636.
24. Zhang W, He L, Yuan Z, et al. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum Gene Ther 1999;10:1151-1161.
25. Heiser A, et al. J. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfecred with amplified tumor RNA. J Immunol 2001;166:2953-2960.
26. Grunebach F, Muller MR, Nencioni A, Brossart P. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 2003;10:367-374.
27. Kobayashi T, et al. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 2003;52:632-637.
28. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001;61:3388-3393.
29. Heiser A, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109:409-417.
30. Su Z, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003; 63:2127-2133.
31. Van Tendeloo VF, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001;98:49-56.
32. Saeboe-Larssen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 2002;259:191-203.
33. Van Meirvenne S, et al. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002;9:787-797.
34. Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003;101:977-982.
35. Muller MR, Grunebach F, Nencioni A, Brossart P. Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol 2003; 170:5892-5896.
36. + T-cell responses and tumor immunity. Blood 2003; 102:4137-4142.
37. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 1996;184:485-492.
38. HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC, Zehl II. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-994.
39. Rees W, et al. An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc Natl Acad Sci USA 1999;96:9781-9786.
40. Anderton SM, Radu CG, Lowrey PA, Ward ES, Wraith DC. Negative selection during the peripheral immune response to antigen. J Exp Med 2001;193:1-11.
41. + T cells. J Immunol 2003; 170:1822-1829.
42. Wherry EJ, McElhaugh MJ, Eisenlohr LC. Generation of CD8(+) T cell memory in response to low, high, and excessive levels of epitope. J Immunol 2002; 168:4455-4461.
43. Thery C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol 2001;13:45-51.
44. Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res 1998;58:2965-2968.
45. Watts C, Amigorena S. Antigen traffic pathways in dendritic cells. Traffic 2000;1:312-317.
46. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-258.
47. Engelmayer J, et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 1999;163:6762-6768.
48. + dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Ther 2000; 7:249-254.
49. Jenne L, Hauser C, Arrighi JF, Saurat JH, Hugin AW. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene Ther 2000;7:1575-1583.
50. Palmowski MJ, et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002;168:4391-4398.
51. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999; 17:51-88.
52. Ni H, et al. Extracellular mRNA induces dendritic cell activation by stimulating tumor necrosis factor-alpha secretion and signaling through a nucleotide receptor. J Biol Chem 2002;277:12689-12696.
53. + T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-594.
54. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999; 189:753-756.
55. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188:2199-2204.
56. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000;12:677-686.
57. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994; 179:1215-1224.
58. Greenberg PD, Kern DE, Cheever MA. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 1985;161:1122-1134.
59. + T cell-dependent tumor rejection. J Exp Med 1991;174:1291-1298.
60. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368.
61. Wu TC, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995;92:11671-11675.
62. Bodmer H, Viville S, Benoist C, Mathis D. Diversity of endogenous epitopes bound to MHC dass II molecules limited by invariant chain. Science 1994;263:1284-1286.
63. Dodi AI, et al. The invariant chain inhibits presentation of endogenous antigens by a human fibroblast cell line. Eur J Immunol 1994;24:1632-1639.
64. Long EO, LaVaute T, Pinet V, Jaraquemada D. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide. J Immunol 1994;153:1487-1494.
65. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001;193:F5-F9.
66. Morelli AE, Hackstein H, Thomson AW. Potential of tolerogenic dendritic cells for transplantation. Semin Immunol 2001;13:323-335.
67. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002;23:445-449.
68. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
69. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-238.
70. Roudier MP, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646-653.
71. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999;11:263-270.
72. Oosterwijk E, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489-494.
73. Jonuleit H, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135-3142.
74. Thurner B, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
75. Gleave ME, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998;338:1265-1271.
76. Luft T, et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 2002;100:1362-1372.
77. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002;100:1354-1361.
78. Martin E, O'Sullivan B, Low P, Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 2003;18:155-167.
79. Nair S, et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003;171:6275-6282.
80. Simon RM, et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001; 19:1848-1854.
81. Green S, Benedetti J, Crowley J. Clinical Trials in Oncology. New York: Chapman & Hall, 1997.
82. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
83. Santulli-Marotto S, Nair SK, Rusconi C, Sullenger B, Gilboa E. Multivalent RNA aptamers that inhibit ctla-4 and enhance tumor immunity. Cancer Res 2003; 63:7483-7489.
84. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3:609-620.
85. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-618.